Education
About Us
Working with TipRanks
Follow Us
Can-Fite BioPharma (CANF)
:CANF
Total Valuation
Can-Fite BioPharma has a market cap or net worth of $14.49M. The enterprise value is $9.57M.
Market Cap$14.49M
Enterprise Value$9.57M
Share Statistics
Can-Fite BioPharma has 12,977,183 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,977,183
Owned by Insiders―
Owned by Institutions0.12%
Financial Efficiency
Can-Fite BioPharma’s return on equity (ROE) is -1.45 and return on invested capital (ROIC) is -114.17%.
Return on Equity (ROE)-1.45
Return on Assets (ROA)-0.86
Return on Invested Capital (ROIC)-114.17%
Return on Capital Employed (ROCE)-1.15
Revenue Per Employee134.80K
Profits Per Employee-1.58M
Employee Count5
Asset Turnover0.07
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Can-Fite BioPharma is -1.50. Can-Fite BioPharma’s PEG ratio is -0.16.
PE Ratio-1.50
PS Ratio0.00
PB Ratio1.72
Price to Fair Value2.18
Price to FCF-1.87
Price to Operating Cash Flow-1.23
PEG Ratio-0.16
Income Statement
In the last 12 months, Can-Fite BioPharma had revenue of 674.00K and earned -7.88M in profits. Earnings per share was -1.08.
Revenue674.00K
Gross Profit674.00K
Operating Income-8.13M
Pretax Income-7.88M
Net Income-7.88M
EBITDA-8.12M
Earnings Per Share (EPS)-1.08
Cash Flow
In the last 12 months, operating cash flow was -7.64M and capital expenditures -5.00K, giving a free cash flow of -7.64M billion.
Operating Cash Flow-7.64M
Free Cash Flow-7.64M
Free Cash Flow per Share-0.59
Dividends & Yields
Can-Fite BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.00
52-Week Price Change-64.65%
50-Day Moving Average1.18
200-Day Moving Average1.71
Relative Strength Index (RSI)49.59
Average Volume (3m)83.37K
Important Dates
Can-Fite BioPharma upcoming earnings date is Aug 28, 2025, TBA Not Confirmed.
Last Earnings DateMay 22, 2025
Next Earnings DateAug 28, 2025
Ex-Dividend Date―
Financial Position
Can-Fite BioPharma as a current ratio of 4.38, with Debt / Equity ratio of 1.91%
Current Ratio4.38
Quick Ratio4.38
Debt to Market Cap0.00
Net Debt to EBITDA0.58
Interest Coverage Ratio-580.71
Taxes
In the past 12 months, Can-Fite BioPharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Can-Fite BioPharma EV to EBITDA ratio is -436.10, with an EV/FCF ratio of -463.55.
EV to Sales5.26K
EV to EBITDA-436.10
EV to Free Cash Flow-463.55
EV to Operating Cash Flow-463.86
Balance Sheet
Can-Fite BioPharma has $7.89M in cash and marketable securities with $104.00K in debt, giving a net cash position of -$7.78M billion.
Cash & Marketable Securities$7.89M
Total Debt$104.00K
Net Cash-$7.78M
Net Cash Per Share-$0.60
Tangible Book Value Per Share<$0.01
Margins
Gross margin is 100.00%, with operating margin of -1206.23%, and net profit margin of -1169.14%.
Gross Margin100.00%
Operating Margin-1206.23%
Pretax Margin-1169.14%
Net Profit Margin-1169.14%
EBITDA Margin-1205.19%
EBIT Margin-1206.23%
Analyst Forecast
The average price target for Can-Fite BioPharma is $4.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.50
Price Target Upside305.41% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―